BioCentury | Feb 6, 2020
Product Development

Early signs CAR NKs could compete with CAR Ts in heme cancers

Early clinical data from CAR NK cells have started to roll in, and hint the modality could compete with CAR T cells on efficacy. Built into CAR NK cells are the benefits of off-the-shelf manufacturing...
BC Innovations | Oct 8, 2019
Distillery Therapeutics

Inhibiting caspase-mediated pyroptosis for graft-versus-host disease

DISEASE CATEGORY: Transplant INDICATION: Graft-versus-host disease (GvHD) Inhibiting CASP4 or CASP5, the human homologs of murine pyroptosis activator CASP11, or the downstream mediators GSDMD and IL-1α could prevent GvHD in leukemia patients undergoing allogeneic hematopoietic...
BC Innovations | Sep 18, 2019
Emerging Company Profile

Divide & Conquer: short-circuiting tumor lines of communication

Divide & Conquer aims to capitalize on new tumor biology that would prevent cancer cells from sharing resistance mechanisms and resensitize the tumor to chemo- and radiotherapy. Medicxi’s David Grainger founded the company in 2018...
BC Innovations | Aug 16, 2019
Targets & Mechanisms

Biotechs explore the next generation of inflammasome targets, with caution

As the NLRP3 field gains momentum, drawing VC and pharma interest for the role the target plays in diseases ranging from NASH to neurodegeneration, biotechs are beginning to eye the next crop of inflammasome targets....
BC Extra | Jun 26, 2019
Company News

June 25 Company Quick Takes: Conatus restructuring; plus Almirall-Dermira, Acer, Glenmark and more

Conatus cuts headcount by 40% to extend runway  Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) said it will lay off 40% of its staff and suspend development of caspase 1 inhibitor CTS-2090 in a bid to extend its...
BC Innovations | Jun 20, 2019
Translation in Brief

Turning Tregs against cancer

Researchers from Massachusetts General Hospital found that inhibiting a signalosome complex in Treg cells could convert the immunosuppressive cell type into inflammatory cells in tumors, a strategy that could both increase the efficacy of checkpoint...
BioCentury | Jun 14, 2019
Product Development

Despite senior management shake-up, Novartis’ pipeline is primed to deliver

A string of departures at Novartis AG and strategic shifts by new CEO Vasant Narasimhan have produced a fairly thorough makeover of the executive committee he inherited in 2018. The team gains a pipeline that...
BC Innovations | Jun 11, 2019
Distillery Therapeutics

CARD11, MALT1 inhibition sensitizes melanoma, colorectal tumors to PD-1 inhibitors

DISEASE CATEGORY: Cancer INDICATION: Melanoma; colorectal cancer Mouse studies suggest inhibiting CARD11 or MALT1 could help sensitize melanoma and colorectal cancer to PD-1 inhibitors. In mouse models of melanoma and colon cancer, conditional knockout of...
BC Extra | Apr 18, 2019
Preclinical News

Pig brain tech could spur stroke therapies, drug and target validation

While Wednesday's announcement that Yale researchers restored cell function in postmortem pig brains sheds no light on the feasibility of reviving consciousness, it does suggest new opportunities for stroke treatments, disease models and validation of...
BC Innovations | Apr 12, 2019
Product Development

NLRP3 early and often

Inflammasome inhibitors could offer a step change for a slew of inflammatory diseases and pharma is taking notice. Two acquisitions in six months show the first inflammasome target -- NLRP3 -- is gaining momentum, but...
Items per page:
1 - 10 of 268